US-based clinical diagnostics company Bio-Techne has signed an agreement to acquire local firm Exosome Diagnostics for a total consideration of approximately $575m.

Under the terms of the deal, Bio-Techne will pay $250m in cash, followed by up to $325m of contingent consideration upon reaching select milestones in the future.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The strategic acquisition, which is scheduled to close in July or August this year, is expected to complement Bio-Techne’s molecular pathology business Advanced Cellular Diagnostics (ACD).

“Under the terms of the deal, Bio-Techne will pay $250m in cash, followed by up to $325m of contingent consideration upon reaching select milestones in the future.”

Exosome Diagnostics’ portfolio comprises a non-invasive urine test called ExoDx Prostate(IntelliScore) (EPI) designed to identify the requirement for prostate biopsy in patients whose PSA test result is not clear. The test is performed on exosomes isolated from urine.

Bio-Techne president and CEO Charles Kummeth said: “ExosomeDx’s technology is a game changer, and positions Bio-Techne to be a leader in the rapidly-growing non-invasive liquid biopsy market.

“This is a very strategic acquisition for us as we also expand in the CAR-T cell marketplace, leveraging our growing critical mass in cell culture-focused product lines.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Bio-Techne plans to utilise its existing position to apply its core competencies to understand exosomes and cell free-DNA (cfDNA) biology and their use as diagnostic tools.

Exosome Diagnostics CEO John Boyce said: “We believe we have found the perfect partner to take our technology to the next level. Both companies share the vision to develop innovative tools that can revolutionise medicine and provide better care for patients.”

Exosome intends to leverage the concept of its exosome- and cfDNA-based analysis technology to develop diagnostics for other cancers.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact